Biocon Share Price in Focus After Biocon Biologics Receives Japan MHLW Marketing Approval for Pegfilgrastim Biosimilar

Biocon Gets Japan MHLW Approval for Pegfilgrastim Biosimilar

Biocon Biologics, the biosimilar arm of Biocon Ltd, has received marketing approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for its Pegfilgrastim biosimilar. Pegfilgrastim is a biologic drug used to prevent infections during chemotherapy by stimulating white blood cell production. The biosimilar is a reference to Neulasta, the original branded Pegfilgrastim marketed by Amgen. Biocon Biologics developed and manufactured the biosimilar, with Global Regulatory Partners Japan acting as the Marketing Authorization Holder in Japan, and Sandoz K.K. (Novartis subsidiary in Japan) as the exclusive commercial partner for promotion, sales, and distribution in Japan.

The Biocon share price was Rs 409.40 in the prior session. Biocon share price had an intraday range of Rs 409 to Rs 414.55. The Japan MHLW approval adds Japan to Biocon Biologics' Pegfilgrastim regulatory portfolio, which already spans multiple global markets.

Click Here and Get Free Investment Predictions

Biocon Pegfilgrastim Japan Approval: Key Details

Parameter	Detail
Product	Pegfilgrastim biosimilar (reference: Neulasta)
Regulator	Japan Ministry of Health, Labour and Welfare (MHLW)
Developer and Manufacturer	Biocon Biologics Ltd (parent entity of Biocon Biologics UK PLC)
Marketing Authorization Holder	Global Regulatory Partners Japan
Commercial Partner in Japan	Sandoz K.K. (exclusive promotion, sales, distribution)
Biocon CMP (prev close)	Rs 409.40
Intraday Range (Aug 24)	Rs 409 to Rs 414.55

Why the Japan MHLW Approval Is Important for Biocon

Japan is the world's third largest pharmaceutical market by value and has historically been one of the more challenging markets for biosimilar approvals due to strict regulatory standards and physician prescribing conservatism. Securing MHLW approval is therefore a significant regulatory milestone for Biocon Biologics. The partnership with Sandoz K.K. (the generics and biosimilars subsidiary of Novartis) is an ideal commercialisation channel in Japan given Sandoz's established regulatory relationships, oncology market access, and distribution infrastructure.

Pegfilgrastim is a high-value biologic used in cancer supportive care across all major global markets. Its entry into Japan through this approval adds to Biocon Biologics' revenue diversification and demonstrates the company's ability to navigate complex regulatory environments beyond its established US and Europe presence in the Nifty Pharma sector.

Screen Biocon on Univest Screener for Fundamentals and Regulatory Track Record

Biocon Share Price Context: About Biocon and Biocon Biologics

Biocon share price reflects one of India's largest biotechnology companies, with Biocon Biologics as its biosimilar-focused subsidiary. Biocon Biologics has a global portfolio of biosimilars covering oncology support care (Pegfilgrastim, G-CSF), diabetes (insulin glargine, insulin aspart), immunology (Adalimumab, Trastuzumab), and ophthalmology (Bevacizumab) segments. The company is one of the largest biosimilar companies in the world by number of approved products across regulated markets.

Download the Univest iOS App or Univest Android App to track Biocon share price and global regulatory approval updates live.

Biocon Share Price: Conclusion

Biocon share price is in focus after Biocon Biologics received marketing approval for its Pegfilgrastim biosimilar from Japan's MHLW. Sandoz K.K. will exclusively sell the product in Japan, adding the world's third largest pharmaceutical market to Biocon Biologics' Pegfilgrastim commercial footprint. Biocon share price was Rs 409.40 in the previous session. Verify all data on NSE and BSE before making any investment decisions.

Frequently Asked Questions

What is the Biocon Japan MHLW approval?

Ans. Biocon Biologics received marketing approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for its Pegfilgrastim biosimilar. The product is a biosimilar to Neulasta (Amgen) developed and manufactured by Biocon Biologics. Sandoz K.K. will exclusively promote and sell the product in Japan.

What is Biocon share price today?

Ans. Biocon share price closed at Rs 409.40 in the previous session (August 24, 2026), with an intraday range of Rs 409 to Rs 414.55.

What is Pegfilgrastim used for?

Ans. Pegfilgrastim is a biologic drug used in cancer supportive care to prevent infections (neutropenia) during chemotherapy by stimulating white blood cell production. Neulasta (Amgen) is the original branded Pegfilgrastim, and Biocon Biologics has developed a biosimilar version.

Who will sell Biocon's Pegfilgrastim in Japan?

Ans. Sandoz K.K., the Japan subsidiary of Sandoz (the generics and biosimilars division of Novartis), will exclusively promote, sell, and distribute Biocon Biologics' Pegfilgrastim biosimilar in Japan. Global Regulatory Partners Japan serves as the Marketing Authorization Holder.

Why is Japan MHLW approval significant for Biocon?

Ans. Japan is the world's third largest pharmaceutical market and has strict biosimilar regulatory standards. MHLW approval adds Japan to Biocon Biologics' Pegfilgrastim regulatory portfolio and opens access to Japanese chemotherapy patients through Sandoz K.K.'s established commercial network.

What is Biocon Biologics' biosimilar portfolio?

Ans. Biocon Biologics has a global biosimilar portfolio spanning oncology support care (Pegfilgrastim, G-CSF), diabetes (insulin glargine, insulin aspart), immunology (Adalimumab, Trastuzumab), and ophthalmology (Bevacizumab). It is one of the world's largest biosimilar companies by number of approved products across regulated markets.